Friday Pop Quiz 5/23/2025
What is the first-line therapy for the mild-moderate disease depicted in the image? A. Narrow-band UVB B. Biologic agents C. Acitretin D. Topical glucocorticoids E. Methotrexate To find out the correct answer and read the explanation, click here. Brought to you by our brand partner    *Brand partners had no involvement in the content of the questions or answers. …
From the JDD Podcast Vault: Evidence-Based Framing for Improving Treatment Adherence
Welcome to our newest blog series, From the JDD Podcast Vault, where we spotlight standout episodes from the JDD Dermatology Podcast, hosted by the always-engaging Dr. Adam Friedman. Each post will revisit compelling conversations that continue to educate, inspire, and provoke thought in dermatologic practice. In this featured episode, “Wondering About Words: Evidence-Based Framing for Improvin …
Over-the-Counter Acne Management: A Comprehensive Update
acneThe management of acne vulgaris has long included a balance between prescription and over-the-counter (OTC) therapies. OTC therapies are typically first-line treatment for most patients, and may be all that is needed to control less severe acne. At the recent Lab to Label Conference, Dr. Hilary Baldwin, a board-certified dermatologist and medical director of the Acne Treatment & Research Cente …
acne
JDD May 2025 Issue Highlights | Special Focus: Skin Cancer
skin cancer This month’s Journal of Drugs in Dermatology issue brings forward a diverse collection of studies spanning surgical, medical, and therapeutic dermatology. The May Editor’s Pick presents a robust cost-effectiveness analysis on placental allograft use for same-day Mohs reconstruction, offering insights from more than 2,000 patients. Also featured are a systematic review of cyl …
skin cancer
Friday Pop Quiz 5/15/2025
            What test should be performed for our patient with the hair loss pictured? A. Serum zinc level B. RPR C. ESR and CRP D. Serum copper level E. Free and total testosterone levels To find out the correct answer and read the explanation, click here. Brought to you by our brand partner    *Brand partners had no …